Why the study?
Does neutralizing monoclonal antibody against VP-1 improve survival and reduce viral replication in athymic mice infected with Theiler's murine encephalomyelitis virus?
Does neutralizing monoclonal antibody against VP-1 improve survival and reduce viral replication in athymic mice infected with Theiler's murine encephalomyelitis virus?
Passive administration of a neutralizing monoclonal antibody against TMEV VP-1 promotes survival, viral clearance, and remyelination in immunodeficient mice.
Answers are grounded in this paper and cite their sources.
Supports antibody strategies in immunodeficient viral models; leaves open translation to human demyelinating disease.
Little or no antiviral immune response is mounted in athymic nude mice infected with the Daniels strain of Theiler's murine encephalomyelitis virus. In these athymic mice, increasing levels of infectious virus could be detected in the central nervous system. Seventy-five percent (9 of 12) of the nude mice were moribund or dead by 4 weeks postinfection. In contrast, treatment of Theiler's virus-infected nude mice with a neutralizing monoclonal antibody (H7-2) against the viral protein VP-1 resulted in a dramatic reduction of infectious virus within the central nervous system. All antibody-treated nude animals survived beyond 4 weeks postinfection. Monoclonal antibody titers could be maintained by passive transfer in treated nude mice at levels comparable to those of polyclonal antibody titers found in heterozygous infected nu/+ littermates. Areas of demyelination were detected in the untreated animals as early as 7 days after infection with little or no remyelination present. In approximately one-half of the antibody-treated nude animals, no demyelinating lesions were found. However, the rest of these treated mice were found to have areas of both demyelination and remyelination. Thus, anti-Theiler's murine encephalomyelitis virus antibody against VP-1 can play a dramatic role in the survival of mice, clearance of virus, limiting viral spread, and altering the pattern of disease in the absence of a functional T-cell response.
No takes yet. Share an insight, caveat, or question.
Fujinami et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: